MLC Runners

We Hate To Run

A quick Internet search will find WebMD articles related to Cancer Treatment Centers of America. This well revered cancer center has partnered with WebMD to reach more people that need cancer care and cancer information. This is an excellent source to gain information on current trends, treatments and news on cancer care. WebMD has been a trustworthy source for well researched articles that relate to the healthcare field. Cancer Treatment Centers of America is excited about this new method of sharing relevant cancer facts, details and up-to-date information. Cancer patients, their worried family members and others can get loads of useful information from these two cancer care specialist groups.

More people are getting their news and other information on the Internet today. With the team of WebMD and Cancer Treatment Centers of America, that people group is who the articles are targeting. It is hoped that people will get needed information that will spur them to contact their physicians if they or loved ones develop any of the cancer symptoms posted on the website. Information on current new cancer programs, research trials and drug therapies are all able to be accessed with just a click of a computer mouse.

Informed individuals are more likely to get checked by a medical professional if they notice specific cancer indicating symptoms. If these people do not know where to turn, they will also find details on cancer care healthcare institutions like Cancer Treatment Centers of America. It is a goal of this partnership to inform more people of their cancer care options. Cancer Treatment Centers of America has been serving cancer patients for decades. Their all-under-one-roof cancer care and supportive therapies provides unique cancer education, treatments, procedures and dietary, mental, emotional and physical support related to cancer. This convenient network is helping millions.

Modern cancer treatments have allowed patients with the most serious forms of the disease to live for periods of time that, in centuries past, were scarcely imaginable. Since the 1950s, diseases like prostate cancer and even lung cancer have become not just fightable but beatable. Initially, these incredible gains in the fight against cancer were attributable primarily to the three main types of cancer treatment that took hold since the 1940s. These were radiation, chemotherapy and surgery. Unfortunately, all of these treatments had horrible side effects, including permanent disability and even death from the treatment itself.

It was the horrible side effects themselves that led to the search for new and more tolerable forms of cancer treatment that would retain or even improve upon the effectiveness of the old treatments. Throughout the late 1980s and 1990s, a new kind of cancer treatment began to take hold. This was known as targeted cancer therapy, a class of drugs that targets the cancer cells individually, leading to the reduction or elimination of many of the terrible side effects associated with such treatment as chemotherapy and radiation.

One of the key figures in the development of targeted cancer therapy has been Clay Siegall. As a researcher for the National Cancer Institute for more than four years and for Bristol-Myers Squibb for almost an entire decade, Dr. Siegall has worked on some of the most cutting-edge targeted cancer treatments in the world today. He was one of the first to begin synthesizing a viable treatment in the form of antibody drug conjugates, a technology that uses human antibodies or synthetic antibodies to deliver a highly lethal cytotoxin directly to the surface of the tumor. This ability to only release the cytotoxin on contact with a malignant tissue virtually eliminates the systemic release of the chemotherapeutic agent into the bloodstream. In theory, this has the capability of completely eliminating all side effects from the treatment.

In 1998, Dr. Siegall went on to found his own company, Seattle Genetics, which was solely dedicated to the development of new forms of antibody drug conjugates. Throughout the 2000’s, Dr. Siegall began zeroing in on a particular form of antibody drug conjugate that would treat a form of cancer, non-Hodgkin’s lymphoma, that had not seen significant improvement over the prior decades.

The resultant drug was ADCetris. Today, ADCetris saves thousands of lives every year.